Human Lysozyme,LZM ELISA Kit

Code CSB-E09135h
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now

Product Details

Target Name
Alternative Names
1 4 beta N acetylmuramidase C ELISA Kit; 1 ELISA Kit; 4-beta-N-acetylmuramidase C ELISA Kit; EC ELISA Kit; LYSC_HUMAN ELISA Kit; Lysosyme ELISA Kit; Lysozyme (renal amyloidosis) ELISA Kit; Lysozyme C ELISA Kit; Lysozyme C precursor ELISA Kit; LYZ ELISA Kit; LZM ELISA Kit; Renal amyloidosis ELISA Kit
Uniprot No.
Homo sapiens (Human)
Sample Types
serum, plasma, tissue homogenates, urine
Detection Range
3.12 ng/mL-200 ng/mL
0.78 ng/mL
Assay Time
Sample Volume
Detection Wavelength
450 nm
Research Area
Assay Principle
Intra-assay Precision (Precision within an assay): CV%<8%      
Three samples of known concentration were tested twenty times on one plate to assess.  
Inter-assay Precision (Precision between assays): CV%<10%      
Three samples of known concentration were tested in twenty assays to assess.    
To assess the linearity of the assay, samples were spiked with high concentrations of human LZM in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)  
1:20 Average % 89  
Range % 83-97  
1:40 Average % 98  
Range % 94-102  
1:80 Average % 96  
Range % 92-101  
1:160 Average % 92  
Range % 88-98  
The recovery of human LZM spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range  
Serum (n=5) 94 90-98  
EDTA plasma (n=4) 98 90-105  
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
ng/ml OD1 OD2 Average Corrected  
200 2.767 2.799 2.783 2.625  
100 2.170 2.189 2.180 2.022  
50 1.475 1.499 1.487 1.329  
25 0.829 0.865 0.847 0.689  
12.5 0.548 0.507 0.528 0.370  
6.25 0.369 0.340 0.355 0.197  
3.12 0.283 0.262 0.273 0.115  
0 0.159 0.157 0.158    
and FAQs
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx

This Human LZM ELISA Kit was designed for the quantitative measurement of Human LZM protein in serum, plasma, tissue homogenates, urine. It is a Sandwich ELISA kit, its detection range is 3.12 ng/mL-200 ng/mL and the sensitivity is 0.78 ng/mL .

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

(From Uniprot)
Lysozymes have primarily a bacteriolytic function; those in tissues and body fluids are associated with the monocyte-macrophage system and enhance the activity of immunoagents.
Gene References into Functions
  1. The findings suggest that the F57I mutation affects the aggregation process of lysozyme resulting in the formation of cytotoxic species and that SAP is able to prevent cell death in the F57I flies by preventing accumulation of toxic F57I structures. PMID: 27428539
  2. the location of specific mutations is an important factor in determining the native-state dynamical properties of human lysozyme PMID: 27926837
  3. rhamnolipid (RL) secreted by Pseudomonas aeruginosa (PA) accelerates proteolysis of lysozyme. PMID: 27931094
  4. Data show increased levels of lysozyme C (LYZ), lacritin (LACRT) and zinc-alpha-2 glycoprotein 1 (AZGP1) in pooled tear fluid sample from Graves' disease (GD) patients with moderate-to-severe Graves' orbitopathy (GO) compared with GD patients without clinical signs of GO. PMID: 28419103
  5. lysozyme cannot be used as a marker of acinar differentiation in salivary tumors. However, lysozyme expression can be helpful to distinguish mammary analog secretory carcinoma from acinic cell carcinoma PMID: 27177644
  6. The preliminary results from the milk yield and milk compositions from a naturally lactating transgenic cloned cow 0906 were also tested. These results provide a solid foundation for the large-scale production of rhLZ in the future. PMID: 26961596
  7. The purpose of this study is to understand the oral mucosal immune status of cancer patients and to make clear whether antibacterial proteins such as salivary secretory immunoglobulin (SIgA) and lysozyme in saliva were influenced by patients' health status and certain medical treatment therapy. PMID: 27294141
  8. Data show that hen lysozyme aggregates faster than the human lysozyme. PMID: 27825804
  9. Data show that transgenic hens with stable expression of recombinant human lysozyme proteins can be created by microinjection of lentiviral vectors. PMID: 25706123
  10. The determination of the structure of a low-population intermediate in the product release process by human lysozyme, is reported. PMID: 25575179
  11. Accumulation of pathogenic lysozymes in the endoplasmic reticulum caused ER stress and the unfolded protein response mainly via the IRE1alpha pathway. PMID: 25659958
  12. Hereditary amyloidosis associated with the p.Trp82Arg lysozyme variant in this new family is predominantly associated with mild upper gastrointestinal tract involvement and in some cases with inflammatory bowel disease. PMID: 25217048
  13. Both mRNA and protein levels of lysozyme were significantly higher in patients with biofilm associated chronic rhinosinusitis (CRS) than those with CRS and no biofilm and controls. PMID: 24121782
  14. Lzm-S can deposit in the systemic vasculature and kidneys in SS, where this deposition could lead to acute organ dysfunction. PMID: 24296430
  15. Lysozyme functions as an antimicrobial peptide, with antibacterial activity. PMID: 16416029
  16. the protective action of lysozyme on the nephrotoxic effects of advanced glycation end products depend on ability to prevent the production and release of inflammatory mediators, such as IL-6 and to reduce macrophage recruitment in the inflammatory sites. PMID: 24495950
  17. Data suggest that the invariant loop of PliC (periplasmic inhibitor of c-type lysozyme) from Brucella abortus plays crucial role in inhibition of human c-type lysozyme via its insertion into the active site cleft of lysozyme. PMID: 24308818
  18. The purpose of this study was to evaluate the effect of chronic alcohol intoxication and smoking on the concentration and output of salivary lysozyme. PMID: 23264227
  19. When Lzm-S was located in close proximity to vascular smooth muscle cells, it could generate H(2)O(2) to produce lengthening in a human cell culture preparation. PMID: 22096116
  20. We observed that expressing the destabilized F57I and D67H lysozymes triggers unfolded protein response activation, resulting in degradation of these variants. PMID: 21965601
  21. increased production of the antibacterial enzyme lysozyme was found in collagenous colitis and lymphocytic colitis PMID: 21460390
  22. The degree of residual structure of lysozyme correlates with the ability of the protein to form amyloid fibrils. PMID: 21574221
  23. Lysozyme is up-regulated in Barrett's mucosa PMID: 21486364
  24. There was no difference in the concentration of lysozyme in children with dental caries than that in controls. PMID: 19563039
  25. Raised plasma lysozyme levels may be a useful biomarker of atherosclerotic cardiovascular disease and response to therapy. PMID: 20167661
  26. a residue at the N-terminal of lysozyme is required for hydrogen bond networks with ordered water molecules and stabilization of the protein. PMID: 10561612
  27. Local cooperativity in the unfolding of an amyloidogenic variant of human lysozyme PMID: 11887182
  28. Positive contribution of hydration structure on the surface of human lysozyme to the conformational stability. PMID: 11927576
  29. Streptococcal inhibitor of complement inhibits two additional components of the mucosal innate immune system: secretory leukocyte proteinase inhibitor and lysozyme. PMID: 12183536
  30. Detailed comparison between the 35 degree C and 4 degree C structures of lysozyme revealed for the first time that an active site lobe has a structural ability to obstruct the polysaccharide-binding cleft only by temperature lowering without a substrate. PMID: 12564923
  31. Structural and folding dynamic properties of human lysozyme T70N variant PMID: 12709420
  32. promyelocytic leukemia protein, but not Sp100, induced the accumulation of MEF in PML nuclear bodies and MEF and PML physically interacted, stimulating MEF transcriptional activity, resulting in the up-regulation of endogenous lysozyme expression. PMID: 14976184
  33. Hydrostatic pressure (3.5 kbar at 57 degrees C, pH 7.4) was used to make amyloidogenic states of WT & variant(Ile56Thr & Asp67His) lysozymes by inducing a conformational state of lysozyme that aggregates readily upon decompression. PMID: 15155566
  34. amyloidogenic variants, I56T and D67H, show a specific, partly unfolded intermediate state under physiologically relevant conditions PMID: 15713462
  35. the ensemble of reduced denatured conformers initially collapses into a large number of unstructured intermediates with one or two disulphide bonds, the majority of which then fold to form the native-like three-disulphide intermediate, des-[77-95] PMID: 16023673
  36. Data suggest that partial unfolding is an intrinsic property of the human lysozyme structure, and suggest that the readiness with which it occurs is a critical feature determining whether or not amyloid deposition occurs in vivo. PMID: 16126226
  37. A novel form of systemic ALys amyloidosis, caused by compound heterozygosity in exon 2 (p.T70N) and exon 4 (p.W112R) of the lysozyme gene (LYZ), with both mutations being present on the same allele. PMID: 16329101
  38. findings indicate that a complex interplay between reduced native-state stability, lower secretion levels, and protein aggregation propensity influences the types of mutation that give rise to familial forms of amyloid disease PMID: 16441658
  39. report a case of hepatic rupture secondary to hereditary lysozyme amyloidosis that was successfully treated by liver transplantation PMID: 16799949
  40. The distortion of the hydrophobic core at the alpha- and beta-interface putatively results in the formation of the initial "seed" for amyloid fibril. PMID: 17054380
  41. The structure of the synthetic human lysozyme was confirmed by high-resolution x-ray diffraction, giving the highest-resolution structure (1.04 A) observed to date for this enzyme. PMID: 17360367
  42. Clusterin, and perhaps other extracellular chaperones, could have a key role in curtailing the potentially pathogenic effects of the misfolding and aggregation of proteins that, like lysozyme, are secreted into the extracellular environment. PMID: 17407782
  43. Thus, we provide a novel strategy for engineering the active site of enzymes. PMID: 17524359
  44. The influence of mutant signal peptides on enzymatic activity of lysozyme at high pH or ionic strength were studied. PMID: 18029788
  45. short-duration, high-intensity exercise increases the secretion rate of salivary Lysozyme despite no change in the saliva flow rate. PMID: 18344136
  46. High salivary lysozyme levels are associated with the odds of hypertension. PMID: 18434581
  47. Lysozyme activity in crevicular fluid and in unstimulated saliva correlated with periodontal pocket depth in donors and in patients with gingivitis or periodontitis. PMID: 19179970

Show More

Hide All

Involvement in disease
Amyloidosis 8 (AMYL8)
Subcellular Location
Protein Families
Glycosyl hydrolase 22 family
Database Links

HGNC: 6740

OMIM: 105200

KEGG: hsa:4069

STRING: 9606.ENSP00000261267

UniGene: Hs.524579

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1